Protocol Ledger

NCT05183035 · Phase III · RECRUITING

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Interventional Phase III clinical trial protocol NCT05183035 sponsored by PedAL BCU in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-01 Enrollment: 130 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05183035
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05183035
Protocol FieldVerified Registry Value
NCT IdentifierNCT05183035
Consolidated Lead SponsorPedAL BCU
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment130 participants (ESTIMATED)
Registered Start Date2022-10-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI